Invesaro

Stocks Health care TRLV

NYSE · Health care

Trulieve Cannabis Corp. (TRLV)

Trulieve Cannabis Corp. brought in $1.1B of revenue over the twelve months to June 30, 2026, down 3.9% from a year earlier. It posted a net loss of $473.3M. Operating cash flow minus capital spending left $228.6M of free cash flow in fiscal 2025. At June 30, 2026 it held $325.4M in cash against $195.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.

Revenue (last 12 months)
$1.1B
-3.9% year on year
Net margin
-41.6%

What Trulieve Cannabis Corp. does

Trulieve Cannabis Corp. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on NYSE under the ticker TRLV.

Revenue and profit by year

Revenue
FY19: $252.8M $252.8M FY19FY21: $521.5M $521.5M FY21FY21: $931.9M $931.9M FY21FY22: $1.2B $1.2B FY22FY23: $1.1B $1.1B FY23FY24: $1.2B $1.2B FY24FY25: $1.2B $1.2B FY25
Net income
FY19: $53.1M $53.1M FY19FY21: $63M $63M FY21FY21: $17.4M $17.4M FY21FY22: -$252.7M -$252.7M FY22FY23: -$526.8M -$526.8M FY23FY24: -$155.1M -$155.1M FY24FY25: -$116.4M -$116.4M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025$1.2B$143.5M-$116.4M-$0.58$228.6M
2024$1.2B$97.8M-$155.1M-$0.79$148.9M
2023$1.1B-$221.6M-$526.8M-$2.28$161.6M
2022$1.2B$50.2M-$252.7M-$0.95-$141.7M
2021$931.9M$204.1M$17.4M$0.21-$263M
2021$521.5M$218.3M$63M$0.93-$298K

Where TRLV ranks in Health care

Revenue$1.2B
#137 of 523 in Health care · Top 26%
Revenue growth-0.4%
#348 of 437 in Health care · Bottom 20%
Net margin-9.9%
#246 of 447 in Health care · Bottom 45%
Free cash flow margin19.4%
#59 of 408 in Health care · Top 14%

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Trulieve Cannabis Corp. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 24, 2026
  2. August 24, 2026
  3. August 11, 2026
  4. August 7, 2026
    Quarterly report 10-Q · period to June 30, 2026
  5. August 7, 2026
  6. August 5, 2026
  7. July 8, 2026
  8. July 2, 2026
  9. June 25, 2026
  10. June 25, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 26, 2026. Insider transactions on SEC

What is TRLV worth? A DCF from its reported cash flow

Insider trades

What the people running Trulieve Cannabis Corp. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about TRLV

What does Trulieve Cannabis Corp. do?

Trulieve Cannabis Corp. is registered with the SEC under industry code SIC 2833 (Medicinal Chemicals & Botanical Products). Its shares trade on NYSE under the ticker TRLV.

Is Trulieve Cannabis Corp. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $473.3M on revenue of $1.1B.

How much revenue does Trulieve Cannabis Corp. make?

Over the twelve months to June 30, 2026 Trulieve Cannabis Corp. reported revenue of $1.1B. That is 3.9% less than a year earlier.

When did Trulieve Cannabis Corp. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the form S-8 POS filing from August 24, 2026.

Similar companies

Compare TRLV with

Compare TRLV with any company

Follow TRLV

Get an email when Trulieve Cannabis Corp. files with the SEC: results, executive changes, material agreements and annual reports.

Follow TRLV: get an email when it files

Where the numbers come from

Financial figures are the values Trulieve Cannabis Corp. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.